Abstract 11195: Transcatheter versus Surgical Aortic Valve Replacement Outcomes Among Solid Organ Transplant Patients: A Systematic Review and Meta-Analysis

Abstract

Introduction: The safety and clinical outcomes of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) among solid organ transplant patients are not well documented. Objective: This study aimed to evaluate the clinical outcomes of TAVR and SAVR among patients with a history of solid organ transplantation. Method: We performed a systematic literature search of databases for relevant articles from inception until April 20, 2022. Result: A total of 342 studies were identified, resulting in 7 studies with a total of 6,128 patients included in the final analysis. The odds of in-hospital mortality (OR 0.29, 95% CI 0.16-0.52, p < 0.0001), blood transfusion (OR 0.30, 95% CI 0.22-0.40 p < 0.00001), postoperative bleeding (OR 0.40, 95% CI 0.33-0.48 p < 0.00001), acute kidney injury (OR 0.50, 95% CI 0.38-0.67 p < 0.00001), and sepsis or infection (OR 0.37, 95% CI 0.25-0.56, p < 0.00001) were significantly lower in patients undergoing TAVR compared to SAVR. Permanent pacemaker implantation was significantly higher in patients who underwent SAVR (OR 2.96, 95% CI 1.98-4.44, p = <0.00001) than those who had TAVR. The odds of 30-day mortality, one-year mortality and acute myocardial infarction were similar between the two groups respectively. Length of hospital stay was significantly lower in patients undergoing TAVR (MD -4.12 mmHg, 95% CI -5.06--3.18, p = <0.00001) compared to those who underwent SAVR. Conclusion: TAVR is confirmed to be advantageous in short term with improved in-hospital survival and lower rates of major complications